刘胜江

2017-06-21


湖南邵东人,80年代在中国从事动物病毒学和免疫学教学科研 (南京农业大学), 并发现和鉴定兔病毒出血症及其病毒 (RHDV)。1993年获得美国堪萨斯州立大学 (Kansas State University)生物化学博士学位。1996年在斯坦福大学 (Stanford University) 完成博士后,从师于诺贝尔医学奖得主阿瑟.科恩伯格博士 (Dr. Arthur Kornberg)。

1996年加入基因泰克公司(Genentech Inc.)生物药开发科学家. 2000年9月创立Abmaxis公司总裁和董事.现就职于拜耳药公司(Bayer Pharmaceuticals)生物药品研发部首席科学家 (Chief Scientist)和全球病原安全负责人 (副总裁)拜耳药公司科学家俱乐部会员。

2006始对太阳能,干细胞,基因编辑和网络数据安全等早期投,任Wearhaus,奥科生物(Oak Biosciences, Inc)和FEDAR GROUP 公司的董事. 曾发表过30篇研究论文,俩篇专箸文章和项发明专利,29多种蛋白和抗体药物研发,250多篇公司研究报告,200多份生药报批文献,被邀在很多国际学术会议中报告演讲和主持,是全球生物药研发(BPOG),非口服药(PDA)联盟的成员。

Dr. Shengjiang Liu, born in Shaodong, Hunan Province. Dr. Liu was trained in animal virology and immunology. He discovered and characterized a new virus that caused rabbit hemorrhagic disease virus (RHDV) in 1984 when he was working in Nanjing Agricultural University. He received his Ph.D. in biochemistry from Kansas State University (1990-1993) and he was the one demonstrating the Ping Pong Bi Bi mechanism of human pyruvate dehygenase complex (PDC) and PDC-kinase regulation which contributes to the regulation of glucose metabolism. He has demonstrated that PDC-E2 is recognized by T- and B-cells of Primary Biliary Cirrhosis (PBC) patients. He had his post doctorial training with Dr. Arthur Kornberg (1959 Noble Laureate) in Stanford University (1993-1996). Dr. Liu was a group leader of Genentech Inc. in process sciences. He founded Abmaxis Inc. in 2000 and served as the president/acting CEO. Abmaxis Inc. was dedicated in development of In Silico Immunization System (ISIM) and therapeutic antibodies for unmet medical needs. Abmaxis was acquired by Merck Co. Inc. 5 years after inception. Dr. Liu is the chief scientist and head (vice president) of biological development-Pathogen Safety. He is responsible for cell bank characterization and testing as well downstream protein purification process development to meet international safety standards. He is an active venture capital investor in early stage companies in biopharmaceuticals/biotect and high technology. He is the chairman of Wearhaus Inc., Oak Bioscience and Fedar Group Inc..

He has over 30 peer-reviewed publications, over 250 biologic development reports, involved in 29 biological drug development and 10 BLA/MAA approvals. Dr. Liu is actively involved in BPOG Biophorium (UK), Parental Drug Association (PDA).

上一篇:肖磊
下一篇:何有文
Powered by 飞色网络